CLARISCAN 376.9 mg/mL

Clariscan 376.9 mg/mL is a gadoterate meglumine injection solution used for magnetic resonance imaging (MRI) contrast enhancement. This intravenous solution aids in improving the visibility of internal structures during MRI scans.

Clariscan 376.9 mg/mL is primarily used as a contrast agent in MRI procedures. It helps to enhance the clarity of images, making it easier for healthcare professionals to detect and diagnose various conditions. The solution is administered intravenously and is commonly used in what is gadoterate meglumine used for, including imaging of the brain, spine, and other internal structures.

Common effects of Clariscan 376.9 mg/mL may include temporary discomfort at the injection site, such as redness or swelling. Some individuals might experience a warm sensation or nausea. These effects are generally mild and short-lived.

Clariscan 376.9 mg/mL should be handled with care, ensuring it is stored and administered under proper medical supervision. It is important to inform healthcare providers of any allergies or pre-existing conditions before use. The solution should be inspected for particles or discoloration before administration.

Clariscan 376.9 mg/mL may interact with certain medications or medical conditions. It is advisable to discuss all current medications and health conditions with a healthcare provider before using this contrast agent. Specific interactions with alcohol or other substances should be reviewed with a medical professional.